Equity Overview
Price & Market Data
Price: $0.027
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $10,558,296
Volume: 0
Performance Metrics
1 Week: 58.82%
1 Month: 8.00%
3 Months: -55.22%
6 Months: -36.17%
1 Year: 21.62%
YTD: -55.00%
Details
Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.